Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer

被引：0

作者：

Petrylak, Daniel P.

Chia, Yen Lin

Yu, Evan Y.

Powles, Thomas

Flaig, Thomas W.

Loriot, Yohann

O'Donnell, Peter H.

Heath, Elisabeth I.

Kojima, Takahiro

Park, Se Hoon

Sonpavde, Guru P.

Picus, Joel

Matsubara, Nobuaki

Obara, Wataru

Chudasama, Vaishali

Poondru, Srinivasu

Harrison, Michael

Kim, Eric

Brancato, Sam Joseph

Rosenberg, Jonathan E.

机构：

[1] Yale Sch Med, New Haven, CT USA

[2] Pfizer Inc, Bothell, WA USA

[3] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[4] Queen Mary Univ London, Barts Canc Inst, London, England

[5] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

[6] Univ Paris Saclay, Gustave Roussy, Univ Paris Sud, Villejuif, France

[7] Univ Chicago, Chicago, IL USA

[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[9] Aichi Canc Ctr, Dept Urol, Nagoya, Aichi, Japan

[10] Samsung Med Ctr, Seoul, South Korea

[11] AdventHlth Canc Inst, Orlando, FL USA

[12] Washington Univ St Louis, St Louis, MO USA

[13] Natl Canc Ctr Hosp East, Chiba, Japan

[14] Iwate Med Univ, Dept Urol, Iwate, Japan

[15] Astellas Pharma US Inc, Northbrook, IL USA

[16] Mem Sloan Kettering Canc Center

[17] , Genitourinary Oncol, New York, NY USA

[18] Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4503

引用

页数：1